Neuromuscular Block Clinical Trial
Official title:
Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.5)
This study is designed to compare recovery times after reversal of a residual neuromuscular block (TOF-ratio 0.5) with different doses of either neostigmine or sugammadex.
Muscle relaxants are integral part of modern anesthesia. They optimize intubating
conditions, reduce laryngeal trauma and improve operating conditions. Drawback is a possible
pharmacological (muscle relaxing) effect of these drugs beyond the end of the operation
(i.e. post-operative residual curarization: PORC). Reportedly about 30% of all patients who
received muscle relaxants show signs of PORC when arriving in the post-anesthesia care unit.
PORC comprises the risk of impaired post-operative fine motor and coordinative skills with a
possible impairment of swallowing pharyngeal secretions with an increased risk of aspiration
after extubation. Possible deleterious effects of this could be pneumonia, bronchitis,
myocardial infarction, cardiac insufficiency, stroke or re-operation.
In order to avoid PORC patients with residual neuromuscular block receive a muscle relaxant
antagonist from the anesthetist at the end of the operation. However, these drugs
(neostigmine, pyridostigmine, etc.) from the class of cholinesterase inhibitors have
unwanted effects such as bradycardia, increased gastro-intestinal motility, post-operative
nausea and vomiting, salivation etc. To decrease these unwanted side effects cholinesterase
inhibitors have to be given in combination with parasympatholyics e.g. atropine or
glycopyrrolate with their own spectrum of unwanted side effects.
From October 2008 on, Sugammadex, a completely new reversal drug was introduced in to
clinical practice. Sugammadex, is a modified gamma-cyclodextrine able to specifically bind
rocuronium (a steroidal muscle relaxant). The complex is eliminated via the kidneys.
However, all studies so far have focussed on reversal of profound or deep neuromuscular
blockade. This study is designed to compare recovery times after reversal of a residual
neuromuscular block (TOF-ratio 0.5) with different doses of either the neostigmine or
sugammadex.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02484651 -
Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?
|
Phase 4 | |
Completed |
NCT01440933 -
Efficacy of Sugammadex in Magnesium Pretreated Patients
|
Phase 2 | |
Recruiting |
NCT02778945 -
Neuromuscular Blockade for Optimising Surgical Conditions During Spinal Surgery
|
Phase 4 | |
Recruiting |
NCT02966249 -
Dexmetomidine Intrathecally and Intravenously Additionally to Spinal Anaesthesia, in Total Knee Arthroplasty
|
Phase 4 | |
Completed |
NCT02838134 -
Deep Versus Moderate Muscle Relaxation During Laparoscopic Donor Nephrectomy in Enhancing Postoperative Recovery
|
Phase 4 | |
Completed |
NCT03734250 -
D Vitamin Effects on Neuromuscular Blocker Reverse Time
|
||
Not yet recruiting |
NCT03287388 -
MRI Measurement of the Effects of Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopy
|
N/A | |
Completed |
NCT01791036 -
Adductor Canal Block In Anterior Cruciate Ligament (ACL) Repair
|
N/A | |
Not yet recruiting |
NCT02648503 -
Deep Neuromuscular Block and Sugammadex Versus Standard of Care on Quality of Recovery in Patient Undergo Elective Laparoscopic Cholecystectomy
|
Phase 4 | |
Completed |
NCT02483611 -
Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block
|
Phase 4 | |
Completed |
NCT02320734 -
Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy
|
Phase 4 | |
Recruiting |
NCT05005676 -
Evaluation of the New Acceleromyograph TOF 3D
|
N/A | |
Not yet recruiting |
NCT03460509 -
Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery
|
Phase 4 | |
Completed |
NCT00828373 -
The Influence of Intravenous Lidocaine on the Action of the Neuromuscular Blocker Rocuronium
|
Phase 4 |